Eli Lilly shares soar on profit outlook, demand for weight-loss drug
Eli Lilly shares indicated higher after its 2024 profit forecast beat Wall Street estimates.
IGTV's Angeline Ong looks at why Eli Lilly and rival Novo Nordisk are likely to see their shares underpinned by the current supply and demand landscape for the drugs they produce.
(AI Video Summary)
Eli Lilly and Novo Nordisk share prices on the rise
The pharmaceutical company Eli Lilly & Co is expecting a huge profit in 2024 because more and more people are looking for drugs to help them lose weight. This is great news for the company, but it also means that there might not be enough of these drugs to go around. Eli Lilly's biggest competitor in this market, Novo Nordisk, is also experiencing success in the weight loss drug business. In fact, Novo Nordisk has even bought another company called Catalent to help them make and sell these drugs. Despite this, there might still not be enough of the ingredients needed to make these drugs.
Potential developments in the medical field
Because of the high demand for weight loss drugs, the prices of these pharmaceutical companies' stock are going up. And it's not just weight loss that these drugs could help with - they might also have other benefits, like improving fatty liver, metabolic dysfunction, sleep apnea, and chronic kidney disease. If the test results for these drugs continue to be positive and the companies keep expanding their facilities to make more of them, there is even more potential for profit.
This is especially likely because many people nowadays lead sedentary lifestyles and spend a lot of time looking at screens. These habits can lead to weight gain and more people wanting to find ways to lose weight. So, if you're thinking of investing in a pharmaceutical company, Eli Lilly and Novo Nordisk might be good options to consider.
This information has been prepared by IG, a trading name of IG Markets Limited. In addition to the disclaimer below, the material on this page does not contain a record of our trading prices, or an offer of, or solicitation for, a transaction in any financial instrument. IG accepts no responsibility for any use that may be made of these comments and for any consequences that result. No representation or warranty is given as to the accuracy or completeness of this information. Consequently any person acting on it does so entirely at their own risk. Any research provided does not have regard to the specific investment objectives, financial situation and needs of any specific person who may receive it. It has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication. Although we are not specifically constrained from dealing ahead of our recommendations we do not seek to take advantage of them before they are provided to our clients.
Seize a share opportunity today
Go long or short on thousands of international stocks.
- Increase your market exposure with leverage
- Get spreads from just 0.1% on major global shares
- Trade CFDs straight into order books with direct market access
Live prices on most popular markets
- Forex
- Shares
- Indices
